Results 71 to 80 of about 1,913,070 (304)

Comparison of microRNA expression in high-count monoclonal B-cell lymphocytosis and Binet A chronic lymphocytic leukemia

Revista Brasileira de Hematologia e Hemoterapia
Background Evidence suggests that monoclonal B-cell lymphocytosis precedes all chronic lymphocytic leukemia cases, although the molecular mechanisms responsible for disease progression are not understood.
Felipe Magalhães Furtado, Priscila Santos Scheucher, Bárbara Amélia Santana, Dalila Lucíola Zanette, Rodrigo do Tocantins Calado, Eduardo Magalhães Rego, Daniel Mazza Matos, Roberto Passetto Falcão   +7 more
doaj   +1 more source

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia

Medical Mycology Case Reports, 2019
Cerebral abscess due to Aspergillus species is a relatively uncommon presentation, even amongst immunocompromised patients. However it is increasingly being recognized as a complication of ibrutinib therapy in patients with chronic lymphocytic leukemia ...
Rohan Beresford, Virginia Dolot, Hong Foo   +2 more
doaj   +1 more source

Epigenetics and chronic lymphocytic leukemia [PDF]

American Journal of Hematology, 2006
The DNA methylation level in patients with chronic lymphocytic leukemia is generally lower than healthy individuals. Although DNA methylation is globally decreased, regional hypermethylation of gene promoters leads to gene silencing. Many of these genes have tumor suppressor phenotypes.
openaire   +2 more sources

Phase II Study of Posttransplant Cyclophosphamide‐Based Graft‐Versus‐Host Disease Prophylaxis After HLA‐Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort

American Journal of Hematology, EarlyView.
ABSTRACT Posttransplant cyclophosphamide (PTCy) to prevent graft‐versus‐host disease (GVHD) improves outcomes in recipients of HLA mismatched unrelated donor (MMUD) allogeneic hematopoietic cell transplantation (allo HCT). Outcomes of MMUD HCT using PTCy in patients requiring reduced intensity or non‐myeloablative conditioning (RIC/NMA) are not well ...
Brian C. Shaffer, Monzr M. Al Malki, Antonio Martin Jimenez Jimenez, Joseph Stanek, Stephanie Bo‐Subait, Brent R. Logan, Jianqun Kou, Erin Leckrone, Heather E. Stefanski, Stephen R. Spellman, Craig Malmberg, Medhat Askar, Rachel Cusatis, Dipenkumar Modi, Farhad Khimani, Mehdi Hamadani, Martin Maiers, Rachel Cook, Karen Ballen, Javier Bolaños‐Meade, Uttam Rao, Jordan Milner, Ramzi Abboud, Katarzyna Jamieson, George Carrum, Bhagirathbhai Dholaria, William J. Hogan, Ran Reshef, Satyajit Kosuri, Alison Loren, Karilyn Larkin, Sally Arai, Muna Qayed, Sung Won Choi, Larisa Broglie, Jeffery J. Auletta, Bronwen E. Shaw, Steven M. Devine, Mahasweta Gooptu   +38 more
wiley   +1 more source

AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments

Haematologica, 2012
Background Interactions with the microenvironment, such as bone marrow mesenchymal stromal cells and nurse-like cells, protect chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis.
Basile Stamatopoulos, Nathalie Meuleman, Cécile De Bruyn, Karlien Pieters, Philippe Mineur, Christine Le Roy, Stéphane Saint-Georges, Nadine Varin-Blank, Florence Cymbalista, Dominique Bron, Laurence Lagneaux   +10 more
doaj   +1 more source

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior

Haematologica, 2010
Background The concept of “accelerated” chronic lymphocytic leukemia is frequently used by both pathologists and clinicians. However, neither histological criteria to define this form of chronic lymphocytic leukemia nor its clinical correlates and ...
Eva Giné, Antoni Martinez, Neus Villamor, Armando López-Guillermo, Mireia Camos, Daniel Martinez, Jordi Esteve, Xavier Calvo, Ana Muntañola, Pau Abrisqueta, Maria Rozman, Ciril Rozman, Francesc Bosch, Elias Campo, Emili Montserrat   +14 more
doaj   +1 more source

The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding

Animal Research and One Health, EarlyView.
A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang, Weiran Wu, Qingqing Cai, Jiaxing Wang, Qi Gao, Muhammad Iftikhar, Yulin Bi, Hao Bai, Lihong Gu, Guobin Chang, Shihao Chen   +10 more
wiley   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Extended lymphadenectomy for high-risk prostate cancer in patients with chronic lymphocytic leukemia may not be necessary: a report of two cases

BMC Cancer, 2019
Background Chronic lymphocytic leukemia is a malignancy with good prognosis. However, the incidence of secondary tumors increases every year after the diagnosis of chronic lymphotcytic leukemia. One of the induced secondary tumors is prostate cancer. For
Yinjie Zhu, Yanqing Wang, Zhiyu Qian, Jiahua Pan, Qiang Liu, Baijun Dong, Wei Xue   +6 more
doaj   +1 more source

[Chronic lymphocytic leukemia].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2014
Currently, several novel drugs are available for chronic lymphocytic leukemia (CLL) in Western countries. Of these drugs, those that inhibit the B-cell receptor (BCR) signaling pathway are the most promising. Ibrutinib inhibits BTK in the BCR pathway and can be administered orally. The results of several clinical trials suggest that ibrutinib is highly
openaire   +3 more sources